Nat Immunol:厦门大学研究团队发表自身免疫疾病研究成果

2017-05-17 佚名 生物帮

2017年5月15日,国际学术权威刊物自然出版集团旗下、免疫学领域顶级期刊《Nature Immunology》杂志上在线发表了厦门大学生命科学学院细胞应激生物学国家重点实验室陈兰芬教授和周大旺教授研究团队与厦门大学附属第一医院、浙江大学、美国德克萨斯大学等单位合作完成的题为“The transcriptional coactivator TAZ regulates reciprocal diff

2017年5月15日,国际学术权威刊物自然出版集团旗下、免疫学领域顶级期刊《Nature Immunology》杂志上在线发表了厦门大学生命科学学院细胞应激生物学国家重点实验室陈兰芬教授和周大旺教授研究团队与厦门大学附属第一医院、浙江大学、美国德克萨斯大学等单位合作完成的题为“The transcriptional coactivator TAZ regulates reciprocal differentiation of TH17 cells and Treg cells”研究论文。研究发现了Hippo信号通路转录共激活因子TAZ在决定CD4+初始T细胞分化为促进炎症的TH17效应细胞和抑制免疫反应的Treg调节性细胞过程中发挥着关键作用。

自身免疫性疾病是一类机体对自身抗原发生免疫反应而导致自身多器官、组织受累的慢性炎症性疾病,如克罗恩肠炎、类风湿性关节炎和干燥综合征等。目前大量研究表明,机体内促炎症的TH17细胞和抑制炎症Treg细胞在类群数量和活化状态的失衡是造成自身免疫疾病的主要致病因素。陈兰芬教授和周大旺教授团队的前期研究发现,小鼠中Hippo信号通路中激酶Mst1/2缺失导致免疫缺陷,机体易受病原体感染并伴随着严重自身免疫疾病。随后,法国与德国研究人员发现一种人类家族遗传性的免疫缺陷及自身免疫病综合征是由于Mst1基因功能缺失突变造成的。2015年,陈兰芬教授和周大旺教授研究团队发现Mst1/2基因缺失导致吞噬细胞的线粒体无法募集到吞噬体周边导致损伤性ROS产生缺陷,从而导致机体病原体杀伤能力下降。该成果解析了人的Mst1基因缺失或Rac2基因突变引发免疫缺陷综合症的致病机理,证明了Mst1/2激酶在天然免疫和宿主防御中发挥着重要作用,为研究人类感染性疾病提供了全新的视角。

在本项研究中,该团队应用CyTOF2质谱流式细胞仪,针对Hippo信号通路关键成员在T细胞特异性敲除小鼠,利用KLH模型分析发现,与野生型小鼠相比Mst1/2敲除后TH17细胞亚群数量显着上升与之相对应的Treg细胞亚群大量减少;而当被Mst1/2抑制的下游效应分子TAZ敲除后,这两类亚群细胞数量呈现相反的变化。进一步研究发现,CD4+初始T细胞分化为促进炎症的TH17效应细胞过程中TAZ表达显着上调,更重要的是通过分析类风湿性关节炎和干燥综合征病人的外周血记忆性T细胞后发现,TAZ与TH17细胞的核心转录因子RORyt的表达呈正相关。这说明TAZ的大量表达对于促进TH17细胞的分化及其介导的炎症性疾病的发生十分重要。

针对TAZ在TH17细胞培养分化条件下被诱导表达的现象,在深入的研究发现,诱导TH17细胞分化的两大信号IL-6和TGF-b下游的转录因子Smad3和STAT3协同促进TAZ基因的转录和表达。利用超高分辨率显微镜GE OMX V4观察和生化手段验证后发现,多聚化的TAZ能够同时与TH17细胞的核心转录因子RORyt和Treg细胞关键转录因子Foxp3形成复合物,TAZ能够促进RORyt转录活性但抑制Foxp3的功能,从而促进TH17细胞的分化和减弱Treg细胞的产生。

颇为有趣的是,他们发现初始T细胞分化为Treg细胞时,Hippo信号通路下游主要转录因子TEAD1的表达量明显上升,并且与RORyt、Foxp3或TEAD1相比TAZ与TEAD1具有更高的亲和力,从而阻断了TAZ与RORyt或Foxp3的相互作用,继而增强了初始T细胞分化为Treg细胞的能力。通过小鼠模型和细胞体外分化发现,当缺失TAZ或过表达TEAD1后,可以大幅提高初始T细胞分化为Treg细胞的能力,然而在初始T细胞中过表达TAZ,特别是突变与TEAD1作用位点的TAZ突变体后,能显着增强其分化为TH17细胞的能力。

研究阐明了TAZ在调节CD4+初始T细胞分化为TH17细胞和Treg细胞的过程中发挥着关键调控作用及其重要机理。该项研究对多种自身免疫性疾病的发病机理提供理论依据,也为早期诊断和治疗慢性炎症性疾病提供可能的分子标志物和治疗靶标。




版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (15)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1660664, encodeId=79761660664ed, content=<a href='/topic/show?id=803c3e216cf' target=_blank style='color:#2F92EE;'>#厦门#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37216, encryptionId=803c3e216cf, topicName=厦门)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a25130440, createdName=xqptu, createdTime=Thu Jun 29 06:48:00 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070411, encodeId=9e0620e041135, content=<a href='/topic/show?id=f30de0713e1' target=_blank style='color:#2F92EE;'>#疾病研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70713, encryptionId=f30de0713e1, topicName=疾病研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Feb 16 05:48:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882047, encodeId=4370188204e8a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Oct 09 21:48:00 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898446, encodeId=374a18984462b, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun Dec 31 22:48:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810791, encodeId=2f4a1810e9167, content=<a href='/topic/show?id=f51a8635118' target=_blank style='color:#2F92EE;'>#自身免疫疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86351, encryptionId=f51a8635118, topicName=自身免疫疾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Tue Aug 15 12:48:00 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=200009, encodeId=cb1920000956, content=我一直觉得自身免疫性疾病很是焦灼, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161015/IMG5801C4A734E137989.jpg, createdBy=51871947992, createdName=1070030296, createdTime=Fri May 19 14:10:10 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511234, encodeId=7cb1151123492, content=<a href='/topic/show?id=3f922910088' target=_blank style='color:#2F92EE;'>#免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29100, encryptionId=3f922910088, topicName=免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a3610309283, createdName=晓辰, createdTime=Fri May 19 07:48:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570044, encodeId=928a15e0044c3, content=<a href='/topic/show?id=f60de338081' target=_blank style='color:#2F92EE;'>#研究团队#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73380, encryptionId=f60de338081, topicName=研究团队)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15c315623764, createdName=changhe718, createdTime=Fri May 19 07:48:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587085, encodeId=2f6b158e08515, content=<a href='/topic/show?id=6c1786352c6' target=_blank style='color:#2F92EE;'>#自身免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86352, encryptionId=6c1786352c6, topicName=自身免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc0d17427282, createdName=gao_jian4223, createdTime=Fri May 19 07:48:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199484, encodeId=12c71994844f, content=自身免疫疾病研究领域取得的重大突破,这项成果使我国基础领域研究走在世界前列!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e97e27354, createdName=lcm1028, createdTime=Thu May 18 07:21:42 CST 2017, time=2017-05-18, status=1, ipAttribution=)]
    2017-06-29 xqptu
  2. [GetPortalCommentsPageByObjectIdResponse(id=1660664, encodeId=79761660664ed, content=<a href='/topic/show?id=803c3e216cf' target=_blank style='color:#2F92EE;'>#厦门#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37216, encryptionId=803c3e216cf, topicName=厦门)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a25130440, createdName=xqptu, createdTime=Thu Jun 29 06:48:00 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070411, encodeId=9e0620e041135, content=<a href='/topic/show?id=f30de0713e1' target=_blank style='color:#2F92EE;'>#疾病研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70713, encryptionId=f30de0713e1, topicName=疾病研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Feb 16 05:48:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882047, encodeId=4370188204e8a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Oct 09 21:48:00 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898446, encodeId=374a18984462b, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun Dec 31 22:48:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810791, encodeId=2f4a1810e9167, content=<a href='/topic/show?id=f51a8635118' target=_blank style='color:#2F92EE;'>#自身免疫疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86351, encryptionId=f51a8635118, topicName=自身免疫疾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Tue Aug 15 12:48:00 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=200009, encodeId=cb1920000956, content=我一直觉得自身免疫性疾病很是焦灼, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161015/IMG5801C4A734E137989.jpg, createdBy=51871947992, createdName=1070030296, createdTime=Fri May 19 14:10:10 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511234, encodeId=7cb1151123492, content=<a href='/topic/show?id=3f922910088' target=_blank style='color:#2F92EE;'>#免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29100, encryptionId=3f922910088, topicName=免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a3610309283, createdName=晓辰, createdTime=Fri May 19 07:48:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570044, encodeId=928a15e0044c3, content=<a href='/topic/show?id=f60de338081' target=_blank style='color:#2F92EE;'>#研究团队#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73380, encryptionId=f60de338081, topicName=研究团队)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15c315623764, createdName=changhe718, createdTime=Fri May 19 07:48:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587085, encodeId=2f6b158e08515, content=<a href='/topic/show?id=6c1786352c6' target=_blank style='color:#2F92EE;'>#自身免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86352, encryptionId=6c1786352c6, topicName=自身免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc0d17427282, createdName=gao_jian4223, createdTime=Fri May 19 07:48:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199484, encodeId=12c71994844f, content=自身免疫疾病研究领域取得的重大突破,这项成果使我国基础领域研究走在世界前列!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e97e27354, createdName=lcm1028, createdTime=Thu May 18 07:21:42 CST 2017, time=2017-05-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1660664, encodeId=79761660664ed, content=<a href='/topic/show?id=803c3e216cf' target=_blank style='color:#2F92EE;'>#厦门#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37216, encryptionId=803c3e216cf, topicName=厦门)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a25130440, createdName=xqptu, createdTime=Thu Jun 29 06:48:00 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070411, encodeId=9e0620e041135, content=<a href='/topic/show?id=f30de0713e1' target=_blank style='color:#2F92EE;'>#疾病研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70713, encryptionId=f30de0713e1, topicName=疾病研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Feb 16 05:48:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882047, encodeId=4370188204e8a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Oct 09 21:48:00 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898446, encodeId=374a18984462b, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun Dec 31 22:48:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810791, encodeId=2f4a1810e9167, content=<a href='/topic/show?id=f51a8635118' target=_blank style='color:#2F92EE;'>#自身免疫疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86351, encryptionId=f51a8635118, topicName=自身免疫疾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Tue Aug 15 12:48:00 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=200009, encodeId=cb1920000956, content=我一直觉得自身免疫性疾病很是焦灼, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161015/IMG5801C4A734E137989.jpg, createdBy=51871947992, createdName=1070030296, createdTime=Fri May 19 14:10:10 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511234, encodeId=7cb1151123492, content=<a href='/topic/show?id=3f922910088' target=_blank style='color:#2F92EE;'>#免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29100, encryptionId=3f922910088, topicName=免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a3610309283, createdName=晓辰, createdTime=Fri May 19 07:48:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570044, encodeId=928a15e0044c3, content=<a href='/topic/show?id=f60de338081' target=_blank style='color:#2F92EE;'>#研究团队#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73380, encryptionId=f60de338081, topicName=研究团队)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15c315623764, createdName=changhe718, createdTime=Fri May 19 07:48:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587085, encodeId=2f6b158e08515, content=<a href='/topic/show?id=6c1786352c6' target=_blank style='color:#2F92EE;'>#自身免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86352, encryptionId=6c1786352c6, topicName=自身免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc0d17427282, createdName=gao_jian4223, createdTime=Fri May 19 07:48:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199484, encodeId=12c71994844f, content=自身免疫疾病研究领域取得的重大突破,这项成果使我国基础领域研究走在世界前列!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e97e27354, createdName=lcm1028, createdTime=Thu May 18 07:21:42 CST 2017, time=2017-05-18, status=1, ipAttribution=)]
    2017-10-09 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=1660664, encodeId=79761660664ed, content=<a href='/topic/show?id=803c3e216cf' target=_blank style='color:#2F92EE;'>#厦门#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37216, encryptionId=803c3e216cf, topicName=厦门)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a25130440, createdName=xqptu, createdTime=Thu Jun 29 06:48:00 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070411, encodeId=9e0620e041135, content=<a href='/topic/show?id=f30de0713e1' target=_blank style='color:#2F92EE;'>#疾病研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70713, encryptionId=f30de0713e1, topicName=疾病研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Feb 16 05:48:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882047, encodeId=4370188204e8a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Oct 09 21:48:00 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898446, encodeId=374a18984462b, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun Dec 31 22:48:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810791, encodeId=2f4a1810e9167, content=<a href='/topic/show?id=f51a8635118' target=_blank style='color:#2F92EE;'>#自身免疫疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86351, encryptionId=f51a8635118, topicName=自身免疫疾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Tue Aug 15 12:48:00 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=200009, encodeId=cb1920000956, content=我一直觉得自身免疫性疾病很是焦灼, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161015/IMG5801C4A734E137989.jpg, createdBy=51871947992, createdName=1070030296, createdTime=Fri May 19 14:10:10 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511234, encodeId=7cb1151123492, content=<a href='/topic/show?id=3f922910088' target=_blank style='color:#2F92EE;'>#免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29100, encryptionId=3f922910088, topicName=免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a3610309283, createdName=晓辰, createdTime=Fri May 19 07:48:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570044, encodeId=928a15e0044c3, content=<a href='/topic/show?id=f60de338081' target=_blank style='color:#2F92EE;'>#研究团队#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73380, encryptionId=f60de338081, topicName=研究团队)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15c315623764, createdName=changhe718, createdTime=Fri May 19 07:48:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587085, encodeId=2f6b158e08515, content=<a href='/topic/show?id=6c1786352c6' target=_blank style='color:#2F92EE;'>#自身免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86352, encryptionId=6c1786352c6, topicName=自身免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc0d17427282, createdName=gao_jian4223, createdTime=Fri May 19 07:48:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199484, encodeId=12c71994844f, content=自身免疫疾病研究领域取得的重大突破,这项成果使我国基础领域研究走在世界前列!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e97e27354, createdName=lcm1028, createdTime=Thu May 18 07:21:42 CST 2017, time=2017-05-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1660664, encodeId=79761660664ed, content=<a href='/topic/show?id=803c3e216cf' target=_blank style='color:#2F92EE;'>#厦门#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37216, encryptionId=803c3e216cf, topicName=厦门)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a25130440, createdName=xqptu, createdTime=Thu Jun 29 06:48:00 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070411, encodeId=9e0620e041135, content=<a href='/topic/show?id=f30de0713e1' target=_blank style='color:#2F92EE;'>#疾病研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70713, encryptionId=f30de0713e1, topicName=疾病研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Feb 16 05:48:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882047, encodeId=4370188204e8a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Oct 09 21:48:00 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898446, encodeId=374a18984462b, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun Dec 31 22:48:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810791, encodeId=2f4a1810e9167, content=<a href='/topic/show?id=f51a8635118' target=_blank style='color:#2F92EE;'>#自身免疫疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86351, encryptionId=f51a8635118, topicName=自身免疫疾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Tue Aug 15 12:48:00 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=200009, encodeId=cb1920000956, content=我一直觉得自身免疫性疾病很是焦灼, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161015/IMG5801C4A734E137989.jpg, createdBy=51871947992, createdName=1070030296, createdTime=Fri May 19 14:10:10 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511234, encodeId=7cb1151123492, content=<a href='/topic/show?id=3f922910088' target=_blank style='color:#2F92EE;'>#免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29100, encryptionId=3f922910088, topicName=免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a3610309283, createdName=晓辰, createdTime=Fri May 19 07:48:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570044, encodeId=928a15e0044c3, content=<a href='/topic/show?id=f60de338081' target=_blank style='color:#2F92EE;'>#研究团队#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73380, encryptionId=f60de338081, topicName=研究团队)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15c315623764, createdName=changhe718, createdTime=Fri May 19 07:48:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587085, encodeId=2f6b158e08515, content=<a href='/topic/show?id=6c1786352c6' target=_blank style='color:#2F92EE;'>#自身免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86352, encryptionId=6c1786352c6, topicName=自身免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc0d17427282, createdName=gao_jian4223, createdTime=Fri May 19 07:48:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199484, encodeId=12c71994844f, content=自身免疫疾病研究领域取得的重大突破,这项成果使我国基础领域研究走在世界前列!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e97e27354, createdName=lcm1028, createdTime=Thu May 18 07:21:42 CST 2017, time=2017-05-18, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1660664, encodeId=79761660664ed, content=<a href='/topic/show?id=803c3e216cf' target=_blank style='color:#2F92EE;'>#厦门#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37216, encryptionId=803c3e216cf, topicName=厦门)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a25130440, createdName=xqptu, createdTime=Thu Jun 29 06:48:00 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070411, encodeId=9e0620e041135, content=<a href='/topic/show?id=f30de0713e1' target=_blank style='color:#2F92EE;'>#疾病研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70713, encryptionId=f30de0713e1, topicName=疾病研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Feb 16 05:48:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882047, encodeId=4370188204e8a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Oct 09 21:48:00 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898446, encodeId=374a18984462b, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun Dec 31 22:48:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810791, encodeId=2f4a1810e9167, content=<a href='/topic/show?id=f51a8635118' target=_blank style='color:#2F92EE;'>#自身免疫疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86351, encryptionId=f51a8635118, topicName=自身免疫疾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Tue Aug 15 12:48:00 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=200009, encodeId=cb1920000956, content=我一直觉得自身免疫性疾病很是焦灼, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161015/IMG5801C4A734E137989.jpg, createdBy=51871947992, createdName=1070030296, createdTime=Fri May 19 14:10:10 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511234, encodeId=7cb1151123492, content=<a href='/topic/show?id=3f922910088' target=_blank style='color:#2F92EE;'>#免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29100, encryptionId=3f922910088, topicName=免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a3610309283, createdName=晓辰, createdTime=Fri May 19 07:48:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570044, encodeId=928a15e0044c3, content=<a href='/topic/show?id=f60de338081' target=_blank style='color:#2F92EE;'>#研究团队#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73380, encryptionId=f60de338081, topicName=研究团队)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15c315623764, createdName=changhe718, createdTime=Fri May 19 07:48:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587085, encodeId=2f6b158e08515, content=<a href='/topic/show?id=6c1786352c6' target=_blank style='color:#2F92EE;'>#自身免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86352, encryptionId=6c1786352c6, topicName=自身免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc0d17427282, createdName=gao_jian4223, createdTime=Fri May 19 07:48:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199484, encodeId=12c71994844f, content=自身免疫疾病研究领域取得的重大突破,这项成果使我国基础领域研究走在世界前列!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e97e27354, createdName=lcm1028, createdTime=Thu May 18 07:21:42 CST 2017, time=2017-05-18, status=1, ipAttribution=)]
    2017-05-19 1070030296

    我一直觉得自身免疫性疾病很是焦灼

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1660664, encodeId=79761660664ed, content=<a href='/topic/show?id=803c3e216cf' target=_blank style='color:#2F92EE;'>#厦门#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37216, encryptionId=803c3e216cf, topicName=厦门)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a25130440, createdName=xqptu, createdTime=Thu Jun 29 06:48:00 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070411, encodeId=9e0620e041135, content=<a href='/topic/show?id=f30de0713e1' target=_blank style='color:#2F92EE;'>#疾病研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70713, encryptionId=f30de0713e1, topicName=疾病研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Feb 16 05:48:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882047, encodeId=4370188204e8a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Oct 09 21:48:00 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898446, encodeId=374a18984462b, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun Dec 31 22:48:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810791, encodeId=2f4a1810e9167, content=<a href='/topic/show?id=f51a8635118' target=_blank style='color:#2F92EE;'>#自身免疫疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86351, encryptionId=f51a8635118, topicName=自身免疫疾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Tue Aug 15 12:48:00 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=200009, encodeId=cb1920000956, content=我一直觉得自身免疫性疾病很是焦灼, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161015/IMG5801C4A734E137989.jpg, createdBy=51871947992, createdName=1070030296, createdTime=Fri May 19 14:10:10 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511234, encodeId=7cb1151123492, content=<a href='/topic/show?id=3f922910088' target=_blank style='color:#2F92EE;'>#免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29100, encryptionId=3f922910088, topicName=免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a3610309283, createdName=晓辰, createdTime=Fri May 19 07:48:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570044, encodeId=928a15e0044c3, content=<a href='/topic/show?id=f60de338081' target=_blank style='color:#2F92EE;'>#研究团队#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73380, encryptionId=f60de338081, topicName=研究团队)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15c315623764, createdName=changhe718, createdTime=Fri May 19 07:48:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587085, encodeId=2f6b158e08515, content=<a href='/topic/show?id=6c1786352c6' target=_blank style='color:#2F92EE;'>#自身免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86352, encryptionId=6c1786352c6, topicName=自身免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc0d17427282, createdName=gao_jian4223, createdTime=Fri May 19 07:48:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199484, encodeId=12c71994844f, content=自身免疫疾病研究领域取得的重大突破,这项成果使我国基础领域研究走在世界前列!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e97e27354, createdName=lcm1028, createdTime=Thu May 18 07:21:42 CST 2017, time=2017-05-18, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1660664, encodeId=79761660664ed, content=<a href='/topic/show?id=803c3e216cf' target=_blank style='color:#2F92EE;'>#厦门#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37216, encryptionId=803c3e216cf, topicName=厦门)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a25130440, createdName=xqptu, createdTime=Thu Jun 29 06:48:00 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070411, encodeId=9e0620e041135, content=<a href='/topic/show?id=f30de0713e1' target=_blank style='color:#2F92EE;'>#疾病研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70713, encryptionId=f30de0713e1, topicName=疾病研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Feb 16 05:48:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882047, encodeId=4370188204e8a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Oct 09 21:48:00 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898446, encodeId=374a18984462b, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun Dec 31 22:48:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810791, encodeId=2f4a1810e9167, content=<a href='/topic/show?id=f51a8635118' target=_blank style='color:#2F92EE;'>#自身免疫疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86351, encryptionId=f51a8635118, topicName=自身免疫疾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Tue Aug 15 12:48:00 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=200009, encodeId=cb1920000956, content=我一直觉得自身免疫性疾病很是焦灼, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161015/IMG5801C4A734E137989.jpg, createdBy=51871947992, createdName=1070030296, createdTime=Fri May 19 14:10:10 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511234, encodeId=7cb1151123492, content=<a href='/topic/show?id=3f922910088' target=_blank style='color:#2F92EE;'>#免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29100, encryptionId=3f922910088, topicName=免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a3610309283, createdName=晓辰, createdTime=Fri May 19 07:48:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570044, encodeId=928a15e0044c3, content=<a href='/topic/show?id=f60de338081' target=_blank style='color:#2F92EE;'>#研究团队#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73380, encryptionId=f60de338081, topicName=研究团队)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15c315623764, createdName=changhe718, createdTime=Fri May 19 07:48:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587085, encodeId=2f6b158e08515, content=<a href='/topic/show?id=6c1786352c6' target=_blank style='color:#2F92EE;'>#自身免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86352, encryptionId=6c1786352c6, topicName=自身免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc0d17427282, createdName=gao_jian4223, createdTime=Fri May 19 07:48:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199484, encodeId=12c71994844f, content=自身免疫疾病研究领域取得的重大突破,这项成果使我国基础领域研究走在世界前列!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e97e27354, createdName=lcm1028, createdTime=Thu May 18 07:21:42 CST 2017, time=2017-05-18, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1660664, encodeId=79761660664ed, content=<a href='/topic/show?id=803c3e216cf' target=_blank style='color:#2F92EE;'>#厦门#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37216, encryptionId=803c3e216cf, topicName=厦门)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a25130440, createdName=xqptu, createdTime=Thu Jun 29 06:48:00 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070411, encodeId=9e0620e041135, content=<a href='/topic/show?id=f30de0713e1' target=_blank style='color:#2F92EE;'>#疾病研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70713, encryptionId=f30de0713e1, topicName=疾病研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Feb 16 05:48:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882047, encodeId=4370188204e8a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Oct 09 21:48:00 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898446, encodeId=374a18984462b, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun Dec 31 22:48:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810791, encodeId=2f4a1810e9167, content=<a href='/topic/show?id=f51a8635118' target=_blank style='color:#2F92EE;'>#自身免疫疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86351, encryptionId=f51a8635118, topicName=自身免疫疾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Tue Aug 15 12:48:00 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=200009, encodeId=cb1920000956, content=我一直觉得自身免疫性疾病很是焦灼, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161015/IMG5801C4A734E137989.jpg, createdBy=51871947992, createdName=1070030296, createdTime=Fri May 19 14:10:10 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511234, encodeId=7cb1151123492, content=<a href='/topic/show?id=3f922910088' target=_blank style='color:#2F92EE;'>#免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29100, encryptionId=3f922910088, topicName=免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a3610309283, createdName=晓辰, createdTime=Fri May 19 07:48:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570044, encodeId=928a15e0044c3, content=<a href='/topic/show?id=f60de338081' target=_blank style='color:#2F92EE;'>#研究团队#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73380, encryptionId=f60de338081, topicName=研究团队)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15c315623764, createdName=changhe718, createdTime=Fri May 19 07:48:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587085, encodeId=2f6b158e08515, content=<a href='/topic/show?id=6c1786352c6' target=_blank style='color:#2F92EE;'>#自身免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86352, encryptionId=6c1786352c6, topicName=自身免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc0d17427282, createdName=gao_jian4223, createdTime=Fri May 19 07:48:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199484, encodeId=12c71994844f, content=自身免疫疾病研究领域取得的重大突破,这项成果使我国基础领域研究走在世界前列!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e97e27354, createdName=lcm1028, createdTime=Thu May 18 07:21:42 CST 2017, time=2017-05-18, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1660664, encodeId=79761660664ed, content=<a href='/topic/show?id=803c3e216cf' target=_blank style='color:#2F92EE;'>#厦门#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37216, encryptionId=803c3e216cf, topicName=厦门)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a25130440, createdName=xqptu, createdTime=Thu Jun 29 06:48:00 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070411, encodeId=9e0620e041135, content=<a href='/topic/show?id=f30de0713e1' target=_blank style='color:#2F92EE;'>#疾病研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70713, encryptionId=f30de0713e1, topicName=疾病研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Feb 16 05:48:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882047, encodeId=4370188204e8a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Oct 09 21:48:00 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898446, encodeId=374a18984462b, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun Dec 31 22:48:00 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810791, encodeId=2f4a1810e9167, content=<a href='/topic/show?id=f51a8635118' target=_blank style='color:#2F92EE;'>#自身免疫疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86351, encryptionId=f51a8635118, topicName=自身免疫疾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Tue Aug 15 12:48:00 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=200009, encodeId=cb1920000956, content=我一直觉得自身免疫性疾病很是焦灼, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161015/IMG5801C4A734E137989.jpg, createdBy=51871947992, createdName=1070030296, createdTime=Fri May 19 14:10:10 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511234, encodeId=7cb1151123492, content=<a href='/topic/show?id=3f922910088' target=_blank style='color:#2F92EE;'>#免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29100, encryptionId=3f922910088, topicName=免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a3610309283, createdName=晓辰, createdTime=Fri May 19 07:48:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570044, encodeId=928a15e0044c3, content=<a href='/topic/show?id=f60de338081' target=_blank style='color:#2F92EE;'>#研究团队#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73380, encryptionId=f60de338081, topicName=研究团队)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15c315623764, createdName=changhe718, createdTime=Fri May 19 07:48:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587085, encodeId=2f6b158e08515, content=<a href='/topic/show?id=6c1786352c6' target=_blank style='color:#2F92EE;'>#自身免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86352, encryptionId=6c1786352c6, topicName=自身免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc0d17427282, createdName=gao_jian4223, createdTime=Fri May 19 07:48:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199484, encodeId=12c71994844f, content=自身免疫疾病研究领域取得的重大突破,这项成果使我国基础领域研究走在世界前列!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e97e27354, createdName=lcm1028, createdTime=Thu May 18 07:21:42 CST 2017, time=2017-05-18, status=1, ipAttribution=)]
    2017-05-18 lcm1028

    自身免疫疾病研究领域取得的重大突破,这项成果使我国基础领域研究走在世界前列!

    0

相关资讯

自身免疫性溶血性贫血研究进展

自身免疫性溶血性贫血(autoimmune hemolytic anemia,AIHA)是临床最常见的获得性溶血性疾病之一。不同类型AIHA之间在发病率、病因、发病机制、溶血机制、治疗及预后等方面都存在异质性。近年,关于冷抗体型AIHA、直接Coombs试验阴性AIHA以及AIHA溶血机制的认识逐渐清晰,利妥昔单抗越来越多用于AIHA治疗,其疗效及安全性获得肯定,补体抑制剂等新药也被尝试用于治

Cell:特殊基因开关或帮助开发治疗自身免疫疾病的新型疗法

图片摘自:paleoplan.com -个体机体的基因组成往往在自身免疫疾的发生过程中扮演重要角色,比如多发性硬化症等,但如今研究者们并不清楚为何自身的免疫细胞会进行自我攻击?近日刊登于国际著名杂志Cell上的一篇研究报告中,来自华盛顿大学医学院的研究人员就通过研究鉴别出了自身免疫疾病的潜在治疗靶点,他们发现了一种主要的基因开关或可开启/关闭机体特殊类型免疫细胞的活性。 研究者发现,这种

Clin Gastroenterol H:中国青少年和年轻成年人自身免疫性乳糜泻的患病率分析!

在中国约有2%死亡青少年和年轻成年人乳糜泻的血清标志物检测呈阳性结果。在中国北方主要以小麦为主食的山东省自身免疫性乳糜泻的患病率为0.76%。

JEM:T细胞分化和自身免疫性炎症应答调控机制

2017年4月11日,国际免疫学领域重要的顶级期刊、洛克菲勒大学出版社的旗舰杂志《Journal of Experimental Medicine》在线发表了浙江大学医学院免疫学研究所鲁林荣教授课题组的最新研究成果 “Suppression of Th17 cell differentiation by Misshapen/NIK-related kinase MINK1”,该研究揭示了T细胞分化

Sci Rep:中科院刘青松教授研发出治疗类风湿性关节炎的BTK抑制剂

近日,国际学术权威刊物自然出版集团旗下子刊《Scientific Reports》杂志在线发表了中国科学院合肥物质科学研究院强磁场科学中心研究员刘青松、刘静课题组与安徽医科大学教授魏伟课题组合作发展了一种新型的针对治疗类风湿性关节炎的BTK激酶抑制剂CHMFL-BTK-11。研究题为Irreversible inhibition of BTK kinase by a novel highly se

盘点:自身免疫疾病研究成果汇总

自身免疫疾病是指机体对自身抗原发生免疫反应而导致自身组织损害所引起的疾病。自身抗体的存在与自身免疫性疾病并非两个等同的概念,自身抗体可存在于无自身免疫性疾病的正常人特别是老年人,如抗甲状腺球蛋白、甲状腺上皮细胞、胃壁细胞、细胞核DNA抗体等。本文梅斯医学小编为您盘点自身免疫疾病相关研究进展,与大家分享。【1】JAMA Oncology 小心!常用自身免疫疾病药物有诱发髓系肿瘤的风险